A carregar...

Second Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In Lung Cancers

EGFR mutations identify patients who are more likely to respond to treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) than cytotoxic chemotherapy. The distinct success of the first generation EGFR TKIs erlotinib and gefitinib has been accompanied by the observati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yu, Helena A., Riely, Gregory J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3673302/
https://ncbi.nlm.nih.gov/pubmed/23411383
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!